title: Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007.
authors.forename: Mark
authors.initials: M
authors.lastname: Pegram
authors.forename: Edith A
authors.initials: EA
authors.lastname: Perez
authors.forename: Martine
authors.initials: M
authors.lastname: Piccart
authors.forename: Neil
authors.initials: N
authors.lastname: Spector
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human